PLURIPOTENT STEM CELL FOR TREATMENT OF CEREBRAL INFARCTION
An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.
1 . A cell preparation for treating cerebral infarction, containing pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells.
2 . The cell preparation according to claim 1 , for preventing and/or treating sequelae from cerebral infarction.
3 . The cell preparation according to claim 1 , wherein the pluripotent stem cells positive for SSEA-3 contain a concentrated cell fraction as a result of stimulation by external stress.
4 . The cell preparation according to claim 1 , wherein the pluripotent stem cells are CD105-positive.
5 . The cell preparation according to claim 1 , wherein the pluripotent stem cells are CD117-negative and CD146-negative.
6 . The cell preparation according to claim 1 , wherein the pluripotent stem cells are CD117-negative, CD146-negative, NG2-negative, CD34-negative, vWF-negative and CD271-negative.
7 . The cell preparation according to claim 1 , wherein the pluripotent stem cells are CD34-negative, CD117-negative, CD146-negative, CD271-negative, NG2-negative, vWF-negative, Sox10-negative, Snail-negative, Slug-negative, Tyrp1-negative and Dct-negative.
8 . The cell preparation according to claim 1 , wherein the pluripotent stem cells are pluripotent stem cells having all of the properties indicated below:
(i) low or absent telomerase activity;
(ii) ability to differentiate into any of the three germ layers;
(iii) absence of demonstration of neoplastic proliferation; and,
(iv) self-renewal ability.
9 . The cell preparation described in claim 1 , wherein the pluripotent stem cells have the ability to differentiate into one or more cells selected from the group consisting of nerve cells, glial cells, vascular endothelial cells, and/or microglial cells.